Topic
Nsclc
Recent coverage of Nsclc from across the web.
-
Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer -
Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases -
Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC -
Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer -
Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial -
Thymus radiation is linked to worse outcomes in patients with non-small cell lung cancer -
Brain metabolism predicts survival in advanced non–small cell lung cancer patients
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow